Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

313results about How to "High response rate" patented technology

Using software incorporated into a web page to collect page-specific user feedback concerning a document embedded in the web page

In one embodiment, a system for measuring subjective user reaction concerning a particular web page comprising an embedded document includes a first icon viewable on the particular web page independent of input from a user subsequent to the user accessing the particular web page. The particular web page includes a document embedded in the particular web page. The first icon solicits a subjective user reaction to the particular web page comprising the document embedded in the particular web page from the user independent of input from the user subsequent to the user accessing the particular web page. The first icon receives user input indicating a desire to provide a subjective user reaction to the particular web page including the document embedded in the particular web page. The user input causes a second icon to become viewable on the particular web page. The second icon provides the user an opportunity to provide a subjective user reaction to the particular web page including the document embedded in the particular web page. The system also includes software associated with the second icon that receives the subjective user reaction to the particular web page including the document embedded in the particular web page for reporting to an owner of the document embedded in the particular web page.
Owner:OPINIONLAB

Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase

We analyzed bone marrow from 67 patients from a phase 2 study of farnesyltransferase inhibition with tipifarnib (R115777, ZARNESTRA®), in older adults with previously untreated, poor-risk acute myeloid leukemia (AML) for N-Ras mutations, global gene expression, and/or quantitative PCR (qPCR) of specific genes. Microarray profiling identified a two-gene expression ratio (RASGRP1:APTX) which provided the greatest accuracy for predicting response to tipifarnib. We demonstrated that this classifier could predict response to tipifarnib in an independent set of 54 samples from relapsed or refractory AML, with a NPV and PPV of 92% and 28%, respectively (odds ratio of 4.4). Therefore, in both newly diagnosed and relapsed or refractory AML, this classifier improves the overall response rate by approximately 50% while maintaining a high NPV, and significantly improves patient overall survival. The two-gene classifier was also validated by qPCR in thirty AML samples from the same clinical study demonstrating a negative predictive value (NPV) and positive predictive value (PPV) of 81% and 50%, respectively (odds ratio of 4.3). These data indicate that a simple two-gene expression assay may have utility in diagnosing a population of AML patients who are more likely to respond to tipifarnib.
Owner:JANSSEN DIAGNOSTICS LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products